- Home
- MCRB vs GF Comparison
MCRB vs GF Comparison
Compare MCRB & GF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- GF
- Stock Information
- Founded
- MCRB 2010
- GF 1990
- Country
- MCRB United States
- GF Germany
- Employees
- MCRB N/A
- GF N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- GF Investment Managers
- Sector
- MCRB Health Care
- GF Finance
- Exchange
- MCRB Nasdaq
- GF Nasdaq
- Market Cap
- MCRB 141.9M
- GF 126.8M
- IPO Year
- MCRB 2015
- GF N/A
- Fundamental
- Price
- MCRB $0.80
- GF $8.82
- Analyst Decision
- MCRB Buy
- GF
- Analyst Count
- MCRB 4
- GF 0
- Target Price
- MCRB $5.63
- GF N/A
- AVG Volume (30 Days)
- MCRB 844.5K
- GF 28.1K
- Earning Date
- MCRB 03-04-2025
- GF 01-01-0001
- Dividend Yield
- MCRB N/A
- GF 0.82%
- EPS Growth
- MCRB N/A
- GF N/A
- EPS
- MCRB N/A
- GF N/A
- Revenue
- MCRB $126,325,000.00
- GF N/A
- Revenue This Year
- MCRB N/A
- GF N/A
- Revenue Next Year
- MCRB N/A
- GF N/A
- P/E Ratio
- MCRB N/A
- GF N/A
- Revenue Growth
- MCRB 12856.41
- GF N/A
- 52 Week Low
- MCRB $0.54
- GF $7.38
- 52 Week High
- MCRB $1.53
- GF $9.41
- Technical
- Relative Strength Index (RSI)
- MCRB 46.38
- GF 67.31
- Support Level
- MCRB $0.81
- GF $8.81
- Resistance Level
- MCRB $0.84
- GF $8.99
- Average True Range (ATR)
- MCRB 0.04
- GF 0.10
- MACD
- MCRB 0.00
- GF 0.03
- Stochastic Oscillator
- MCRB 45.58
- GF 77.33
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a United States-based non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.